CardioFocus

Pushing the boundaries of what’s possible in cardiac ablation 🫀 Together with Stereotaxis, we’re bringing the power of robotic precision to pulsed field ablation for the first time! By pairing our proven Centauri PFA System with the MAGiC robotic ablation catheter, this collaboration marks an exciting step toward a new era of robotic PFA innovation. 🔗Read the press release: https://lnkd.in/dxmeFpzM #CentauriPFA #RoboticPFA #PFA #Epeeps Note: The Centauri system is not approved for sale in the United States.

Yesterday in Boston, we had the privilege of hosting another Physician Advisory Board Meeting — bringing together some brilliant minds to dive deeper into our #PFA portfolio: QuickShot™ Nav, OptiShot™, and CardioWave™. Physicians explored QuickShot’s advanced mapping and ablation capabilities, experienced OptiShot’s direct visualization advantage, and discussed how our optimized waveform and catheter design work together to deliver consistent, durable lesions. Hands-on sessions and collaborative discussions made it a truly productive day. We are so grateful to Drs Jacob Koruth, Henry Huang, Hiroshi Nakagawa, Mike Mangrum, Keita Watanabe, and Yasuhiro Shirai for their feedback and continued partnership. Note: The OptiShot™ PFA Balloon System, QuickShot™ Nav and CardioWave™ are investigational and not approved for commercial use.

What an incredible day in Prague at one of our first Physician Advisory Board Meetings! Sharing the latest progress and gaining insight across our #PFA portfolio — QuickShot™ Nav, OptiShot™, and CardioWave™ — and seeing the energy, engagement, and feedback from such a distinguished group of electrophysiologists made the day truly inspiring. A huge thank you to Prof. Petr Neuzil, Dr. Melanie Gunawardene, Dr. Dominik Linz, Dr. Johan Vijgen, Dr. Zdeněk Stárek and Dr. Jim Hansen for bringing your expertise to the discussions and hands-on sessions — your collaboration fuel our momentum and strengthen our confidence in the path ahead. 🚀 Note: The OptiShot™ PFA Balloon System, QuickShot™ Nav and CardioWave™ are investigational and not approved for commercial use.

Today at #FAFA2025, we were proud to share a live OptiShot™ PFA Balloon case from our ongoing VISION-AF trial. A big thank you to Prof. Petr Neuzil and Dr. Moritoshi Funasako at Nemocnice Na Homolce for leading a great case, and to the audience for their engagement and thoughtful questions. Using direct endoscopic visualization and a compliant balloon for optimal tissue contact, this case highlighted how CardioFocus' PFA technology is advancing safer, more effective AFib treatment. During #AFAwarenessMonth, we’re reminded of the millions of patients living with AF and why innovations like OptiShot™ matter. Special thanks to Drs Boris Schmidt and K.R. Julian Chun and the FAFA organizers for making this live case possible. Note: The OptiShot™ PFA Balloon System is investigational and not approved for commercial use.

Tomorrow at the FAFA Symposium in Frankfurt, Prof. Petr Neuzil and his team at Nemocnice Na Homolce Hospital will perform a live case with OptiShot™, CardioFocus’ endoscopically guided PFA balloon. OptiShot is the only balloon-based pulsed field ablation (PFA) system with built-in endoscopic visualization, enabling direct, real-time visualization of pulmonary vein isolation. Early clinical experience has been very promising, and we’re excited to see it highlighted on tomorrow's stage. Catch the live case at 11:20 AM CEST! #FAFA #AFib #PFA #PVI Note: The OptiShot™ PFA Balloon System is investigational and not approved for commercial use.

Congratulations to the team at Crailsheim Hospital on their first Centauri™ PFA case. We’re grateful for our partnership with BIOTRONIK in making it possible to bring this innovative therapy to more patients in Europe!

#BigNews: We’re thrilled to announce our strategic partnership with BIOTRONIK — a collaboration that will expand access to the Centauri™ Pulsed Field Ablation (PFA) System across 17 European countries! With over 8000 patients treated and 40+ clinical publications, Centauri is a leading focal PFA system offering precise control, workflow flexibility, and strong real-world outcomes in the treatment of paroxysmal AF. This partnership allows CardioFocus to bring Centauri to more physicians and patients than ever before, while sharpening our focus on the next frontier in PFA — including our QuickShot™ Nav and OptiShot™ PFA balloon platforms and ongoing clinical trials. We’re proud to join forces with BIOTRONIK to accelerate the future of AFib treatment — together, advancing physician education, innovation, and patient care. 🔗Read the full press release: https://lnkd.in/dVBykQ3Q #CentauriPFA #PFA #Epeeps Note: The Centauri system is not approved for sale in the United States. The OptiShot™ PFA Balloon System and QuickShot™ Nav is investigational and not approved for commercial use.

A New Wave of Independent Centauri Data! In just the past month, EP Europace has published six independent studies examining diverse aspects of pulsed field ablation using the Centauri PFA system. From lesion characterization and safety insights to posterior wall isolation, comparative procedural outcomes, and tailored ablation strategies - these clinical studies reflect the growing momentum and confidence in Centauri's role in AF ablation. 🔍 Explore the research: 1. Stiffness assessment of acute atrial lesions using MR elastography after RFA and PFA |🔗https://lnkd.in/defwZ44i 2. Posterior wall isolation in PeAF: RFA vs PFA (Single-center prospective study) |🔗https://lnkd.in/dphetWYi 3. Hemolysis after PFA for pulmonary vein isolation: A prospective controlled trial |🔗https://lnkd.in/di3m-wN7 4. CENTAURI vs RF ablation: Randomized clinical comparison of procedural outcomes |🔗https://lnkd.in/dCe95pt5 5. Tailored F-PFA for complex atrial substrate: Safety and 6-month outcomes |🔗https://lnkd.in/dujmcwkG 6. CTI flutter ablation using focal monopolar PFA: Procedural feasibility & safety |🔗https://lnkd.in/dBj5vGss Note: CardioFocus is sharing these studies for informational purposes only. All six studies were independently conducted and published.

Another day, another successful live #PFA case at Prague Rhythm 2025 — this time marking the first clinical showcase of our QuickShot™ Nav catheter. Dr. Ante Anic and the stellar team at KBC Split (Croatia) demonstrated the power of QuickShot™ Nav in a PeAF patient using a comprehensive PVI+ approach. With rapid posterior wall and CTI ablations completed in just minutes and first-pass success achieved, the case highlighted QuickShot™ Nav’s unique combination of speed, flexibility, and reliable contact sensing. An exciting step forward as we continue to explore the clinical potential of this next-generation deca-spline mini-basket focal catheter. 📸 Swipe through to see highlights Note: QuickShot™ Nav is investigational and not approved for commercial use.

Today’s OptiShot™ live PFA case at Prague Rhythm 2025 delivered on all fronts! Dr. Vivek Reddy from Homolka Hospital showcased the power of direct visualization and the simplicity of the OptiShot workflow in a PAF patient with four pulmonary veins. Key highlights: ✅Fast procedure time: ~2 minutes per vein ✅Clear endoscopic visualization enabled fine-tuning of contact ✅Stable balloon position maintained throughout despite some coughing response ✅Post-ablation map revealed wide, contiguous isolation lines ✅Single-operator friendly workflow ✅Proprietary waveform + contact-optimized design = efficient lesions The case was preceded by a technical presentation introducing the science, design, and clinical rationale behind OptiShot™ — showcasing the "why" before demonstrating the "how." 📸 Swipe through to see moments from the presentation and the procedure. Note: The OptiShot™ PFA Balloon System is investigational and not approved for commercial use.